Purpose Preclinical studies show that sorafenib, a multitarget kinase inhibitor, displays anti-
proliferative, anti-angiogenic, and pro-apoptotic properties in hepatocellular carcinoma …

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second
largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent …

The approval of sorafenib and active development of many other molecularly targeted
agents in hepatocellular carcinoma (HCC) have presented a challenge to understand the …

Abstract Background & Aims The study aimed to evaluate the tissue expression of molecules
involved in intracellular signalling pathways as predictors of response to sorafenib in …

Background & Aims Sorafenib, an oral multikinase inhibitor, significantly prolonged overall
survival (OS) vs. placebo in patients with unresectable hepatocellular carcinoma (HCC) in …

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Page 1
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Ghassan K …

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of
advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib …

Since sorafenib, a multikinase inhibitor targeting angiogenesis of hepatocellular carcinoma
(HCC), demonstrated survival benefits in recent clinical trials, it has changed the treatment …

Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some
patients with HCC initially respond to sorafenib, but eventually succumb to the disease …

Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven
efficacy against Hepatocellular Carcinoma (HCC). Although the overall clinical efficacy of …